interleukin-6
[대역어] 인터루킨-6
[용어속성] Protein
[용어속성] Protein
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis
코로나19로 입원한 환자에서 토실리주맙, 사릴루맙, 28일 후 모든 원인 사망률 사이의 연관성: 네트워크 메타 분석
Meta-Analysis
[키워드] 28-day mortality
all-cause mortality
antagonist
association
choice
clinician
Consistency
Corticosteroid
Corticosteroids
COVID-19 patient
deaths
demonstrated
dependent on
Effect
eligible patient
Evidence
hospitalised patient
Hospitalised patients
in-hospital mortality
inconsistency
initiated
interleukin-6
interleukin-6 receptor
invasive ventilation
Meta-analysis
Network meta-analysis
Non-invasive
not dependent
Odds ratio
Odds ratios
P-value
Patient
Placebo
randomisation
randomised
randomised comparison
receiving
receptor antagonist
REMAP-CAP
REMAP-CAP trial
sarilumab
Tocilizumab
Trial
usual care
Ventilation
with COVID-19
[DOI] 10.1371/journal.pone.0270668 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1371/journal.pone.0270668 PMC 바로가기 [Article Type] Meta-Analysis
Clinical progress in MSC-based therapies for the management of severe COVID-19
Mini review
[키워드] MB-MSCs
Menstrual blood-derived Mesenchymal Stromal Cells
3-dioxygenase
ACE2angiotensin converting enzyme 2
acute graft-versus-host disease
acute respiratory distress syndrome
Adipose Tissue derived Mesenchymal Stromal Cells
admadministration
administration
alanine aminotransferase
Allo-MSCsAllogeneic Mesenchymal Stromal Cells
Alloallogeneic
Allogeneic
Allogeneic Mesenchymal Stromal Cells
ALTalanine aminotransferase
angiotensin converting enzyme 2
anti-inflammatory property
ARDS
ARDSacute respiratory distress syndrome
Aspartate aminotransferase
ASTaspartate aminotransferase
AT-MSCsAdipose Tissue derived Mesenchymal Stromal Cells
AT2type 2 alveolar cells of the lungs
BALFbronchoalveolar lavage fluid
BM-MSCsbone marrow derived MSCs
body weight
bone marrow derived MSCs
Bronchoalveolar lavage fluid
bwBody weight
C-reactive protein
cAMPcyclic adenosine monophosphate
candidate
CDcluster of differentiation
Cell
clinical
clinical trial
cluster of differentiation
complex
conducted
Coronavirus disease 2019
coronavirus disease of 2019
COVID-19
COVID-19Coronavirus disease of 2019
CRPC-reactive protein
cyclic adenosine monophosphate
cytokine
Daewoong Pharmaceutical’s Mesenchymal Stromal Cells
DCsdendritic cells
dendritic cells
driven by
DSCsPlacenta-derived decidua stromal cells
DW-MSCsDaewoong Pharmaceutical’s Mesenchymal Stromal Cells
EVsextracellular vesicles
Extracellular vesicles
Fas ligands
Fas-LFas ligands
FDAFood and Drug Administration
FGFfibroblast growth factor
fibroblast growth factor
Food and Drug Administration
forkhead box P3 +
FOXP3 +forkhead box P3 +
G-CSFgranulocyte colony-stimulating factor
Gal-1galectin-1
Gal-3galectin-3
Gal-9galectin-9
galectin-1
galectin-3
Galectin-9
GM-CSFgranulocyte macrophage-colony stimulating factor
granulocyte colony-stimulating factor
granulocyte macrophage-colony stimulating factor
growth factor
GvHDacute graft-versus-host disease
HB-AT-MSCsHope Biosciences autologous adipose-derived mesenchymal stromal cells
HdHigh dose
hepatocyte growth factor
HGFhepatocyte growth factor
High dose
HLAHuman leukocyte antigen
Hope Biosciences autologous adipose-derived mesenchymal stromal cells
human leukocyte antigen
ICUIntensive Care Unit
IDOIndoleamine 2
IFN-γinterferon-γ
IL-10interleukin-10
IL-1interleukin-1
IL-1βinterleukin-1β
IL-2 receptor
IL-2interleukin-2
IL-2RIL-2 receptor
IL-4interleukin-4
IL-6interleukin-6
IL-7Interleukin 7
IL-7interleukin-7
IL-8interleukin 8
IL-9interleukin
IL1-αinterleukin 1-α
IL1-βinterleukin 1-β
IL1RaInterleukin-1 receptor antagonist
immune dysregulation
immunological
immunomodulatory
IMVInvasive mechanical ventilation
Indoleamine 2
inducible protein 10
inflammatory process
inhalation
INHinhalation
intensive care unit
interferon-γ
interleukin
interleukin 1-α
interleukin 1-β
Interleukin 7
interleukin 8
interleukin-1
Interleukin-1 receptor antagonist
interleukin-10
interleukin-1β
interleukin-2
Interleukin-4
interleukin-6
interleukin-7
intravenous
Invasive mechanical ventilation
IP-10inducible protein 10
IVintravenous
keratinocyte growth factor
KGFkeratinocyte growth factor
lactate dehydrogenase
LDHlactate dehydrogenase
LdLow dose
lipopolysaccharide
low dose
LPSlipopolysaccharide
major histocompatibility complex
management
MAPKmitogen-activated protein kinase
MCP-1monocyte chemoattractant protein-1
Mesenchymal stromal cell
Mesenchymal stromal cells
MHCMajor Histocompatibility Complex
microRNA
miRNAmicroRNA
MIS-Cmultisystem inflammatory syndrome in children
mitogen-activated protein kinase
monocyte chemoattractant protein-1
MSCs
MSCsmesenchymal stromal cells
multisystem inflammatory syndrome in children
nanovesicles
National Institutes of Health
natural
NETsNeutrophil Extracellular Traps
Neutrophil extracellular traps
NF-κBnuclear factor-kappa B
NIHNational Institutes of Health
nitric oxide
NKnatural
NONitric Oxide
nuclear factor-kappa B
NVsnanovesicles
occur
PD-1programmed cell death protein 1
PD-L1programmed death ligand-1
PGE2prostaglandin E2
pharmacological management
PL-MSCsPlacental-derived Mesenchymal Stromal Cells
Placenta-derived decidua stromal cells
placental expanded
Placental-derived Mesenchymal Stromal Cells
PLX-PADplacental expanded
programmed cell death protein 1
programmed death ligand-1
prostaglandin E2
protein spike
public health
reactive oxygen species
Regulatory T cell
Respiratory failure
RFrespiratory failure
ROSreactive oxygen species
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
Secretome
severe acute respiratory syndrome coronavirus 2
severe COVID-19
Severe respiratory distress
signal transducer activators of transcription-3
Sprotein spike
STAT3signal transducer activators of transcription-3
syndrome
TGF-β1transforming growth factor-β1
TGFtransforming growth factor
the cytokine storm
the disease
therapeutic
therapy
TLRtoll-like receptors
TNF-α-stimulating gene 6
TNF-αtumor necrosis factor-α
TNFTumor Necrosis Factor
Toll-like receptors
transforming growth factor
transforming growth factor-β1
treat
Tregregulatory T cell
TSG-6TNF-α-stimulating gene 6
tumor necrosis factor
tumor necrosis factor-α
type 2 alveolar cells of the lungs
UC-MSCsumbilical cord derived MSCs
umbilical cord derived MSCs
vascular endothelial growth factor
VEGFvascular endothelial growth factor
Wharton’s Jelly–derived Mesenchymal Stromal Cells
WJ-MSCsWharton’s Jelly–derived Mesenchymal Stromal Cells
[DOI] 10.1016/j.cytogfr.2022.07.002 [Article Type] Mini review
[DOI] 10.1016/j.cytogfr.2022.07.002 [Article Type] Mini review
Circulating suPAR associates with severity and in-hospital progression of COVID-19
순환하는 suPAR은 COVID-19의 중증도 및 병원 내 진행과 관련이 있습니다.
Observational Study
[키워드] 95% CI
Accuracy
Admission
Adult patients
age
albumin
assays
association
AUC
best
characterized
clinical
correlated
COVID-19
COVID-19 disease
CRP
discrimination
Disease progression
disease severity
doubling
EGFR
ELISA
females
ferritin
FIVE
Hospital admission
hyperinflammation
IMPROVE
In-hospital
interleukin
interleukin-6
International
Lactate
lactate dehydrogenase
LDH
Linear model
male
marker
median age
observational study
outcome
parameter
patients
patients hospitalized
plasma suPAR
predict
primary outcome measure
procalcitonin
progression
risk stratification
scale
serum albumin
serum lactate
severity
severity of COVID-19
significantly
significantly lower
suPAR
survival
survivor
Treatment
WHO
WHO Clinical Progression Scale
WHO-CPS
[DOI] 10.1111/eci.13794 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1111/eci.13794 PMC 바로가기 [Article Type] Observational Study
Risk factors for progression to acute respiratory failure after casirivimab and imdevimab administration: A retrospective study
카시리비맙 및 임데비맙 투여 후 급성 호흡부전으로 진행되는 위험인자: 후향적 연구
Article
[키워드] Acute respiratory failure
administration
Admission
analyzed
antibody
C-reactive protein
Casirivimab
casirivimab/imdevimab
Characteristics
Chest
Chest computed tomography
Chest radiograph
city
coronavirus disease
COVID-19
Cycle threshold value
detectable
develop
diabete
diabetes
Disease progression
effective
Factor
Glucose
hemoglobin
Hiroshima
Hospitalization
independent
interleukin-6
Logistic regression analysis
Lymphocyte count
median age
monoclonal antibody
multivariate
Outpatient
Patient
patients with COVID-19
patients with diabete
Pneumonia
polymerase chain
progressed
progression
reported
Respiratory failure
Retrospective study
risk factor
severe disease
significantly
therapy
treated
two group
two groups
[DOI] 10.1016/j.resinv.2022.04.005 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.resinv.2022.04.005 PMC 바로가기 [Article Type] Article
Coronary microvascular dysfunction is common in patients hospitalized with COVID-19 infection
코로나19 감염으로 입원한 환자에서 관상동맥 미세혈관 기능장애가 흔하다
Article
[키워드] Admission
Biomarker
Biomarkers
C-reactive protein
control subject
Coronary
coronary microvascular dysfunction
correlated
COVID-19
COVID-19 infection
COVID-19 patient
COVID-19 patients
D-dimer
demonstrated
dimer
disease
driven by
driver
dysfunction
echocardiographic
echocardiography
Evidence
explain
FIBRIN
flow velocity
highest
Hospitalized
Infection
Inflammation
interleukin
interleukin-6
Moderate COVID-19
morbidity
morbidity and mortality
Myocardial
myocardial injury
Patient
patients hospitalized
patients with COVID-19
peptide
resulting
SARS-CoV-2
severe COVID-19
Severe COVID-19 Infection
severity
significantly lower
the patient
tissue
troponin
was done
with COVID-19
[DOI] 10.1111/micc.12757 PMC 바로가기 [Article Type] Article
[DOI] 10.1111/micc.12757 PMC 바로가기 [Article Type] Article
Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study
Research article
[키워드] 28-day mortality
assumed
benefit
Clinical outcome
Cohort
cohort study
comparable
cost-effectiveness
Covid cytokine storm
COVID-19
COVID-19 patient
Critically ill
Critically ill patient
CRP
demonstrated
Dexamethasone
dose
equity
family
feasible
finding
fixed dose
foundation
funding
groups
Inflammation
inhibitor
interleukin-6
no significant difference
pair-wise comparison
Patient
patients
physiological response
receiving
reduce mortality
reduction
response
Scholarship
severe COVID-19
supported
Taylor
the patient
threshold
Tocilizumab
treated
with COVID-19
[DOI] 10.1016/j.lana.2022.100228 [Article Type] Research article
[DOI] 10.1016/j.lana.2022.100228 [Article Type] Research article
Immunologic features of asymptomatic postvaccination infections with the Delta variant of SARS-CoV-2 in adults
성인에서 SARS-CoV-2의 Delta 변이체에 의한 무증상 백신 접종 후 감염의 면역학적 특징
Article
[키워드] accompanied
acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus-2
Adults
Analysis
analyzed
antibody
Antibody titers
Asymptomatic
asymptomatic infection
asymptomatic infections
Breakthrough infection
C-reactive protein
C-reactive protein (CRP
collected
coronavirus disease
Coronavirus disease 2019
Coronavirus-2
correlated
CRP
Cutoff
Day
defined
Delta
delta variant
dose
doses
elevated
feature
Gender
group
groups
highest
IL-6
Immunologic
immunologic features
indicated
infect
Infection
infections
Inflammatory
interleukin
interleukin-6
laboratory data
less
leukocyte
leukocytes
Lymphocytes
Mild
moderate
much lower
ordinal logistic
postvaccination
postvaccination infections.
Retrospective study
risk factor
Risk factors
SARS-CoV-2
SARS-CoV-2 infections
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
severity
signal
signal-to-cutoff ratio
symptomatic
symptomatic and asymptomatic
T-cell
T-cells
the SARS-CoV-2
transmissions
two group
vaccination
Vaccinations
was performed
[DOI] 10.1002/iid3.670 PMC 바로가기 [Article Type] Article
[DOI] 10.1002/iid3.670 PMC 바로가기 [Article Type] Article
Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2
바이러스 감염의 Gal-3BP: 중증 급성 호흡기 증후군 코로나바이러스 2의 새로운 역할
Review
Published on
Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 치료제,
Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 치료제,
[키워드] addition
antiviral activity
antiviral immune response
attenuate
binding
Biomarkers
Cancer
circulating
complex
components
coronavirus 2
correlation
Cytokines
disease
Disease progression
disease severity
evaluate
expression
Factor
Gal-3BP
galectin-3
glycoprotein
HCV
HIV-1
IFNs
IL-6
in viral
induce
Infection
Interaction
interferons
interferons (IFNs
interferons (IFNs)
interleukin
interleukin-6
involved
knowledge
modulation
molecular mechanism
molecular mechanisms
multifunctional
prognostic biomarker
progression
proinflammatory cytokines
Protein
respiratory
role
SARS-CoV-2
severe disease
Severity of disease
Signaling
TGF-β
TNF
TRAF
upregulated
upregulation
Viral diseases
viral infections
virus
virus infection
[DOI] 10.3390/ijms23137314 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/ijms23137314 PMC 바로가기 [Article Type] Review